Organovo Holdings, Inc. Announces Fiscal-Year 2016 First-Quarter Earnings Conference Call

Aug 05, 2015, 08:05 ET from Organovo Holdings, Inc.

SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that its financial results for the first quarter of fiscal year 2016 will be released Monday, August 10, 2015.

The Company will host a conference call at 5:00 p.m. ET to discuss the financial results.  If you would like to participate in the call, please dial-in approximately 10 minutes prior to the start time, and ask to join the Organovo Holdings, Inc. conference call. The dial-in info is as follows:

Participant dial in (toll free): 

1-888-317-6003

Participant international dial in: 

1-412-317-6061

EE TF - Canada

1-866-284-3684

 

You will need to provide the Participant Elite Entry Number: 4892967

A replay will be made available one hour following the live call and remain available for 30 days. To access the replay, the dial-in info is as follows:

US Toll Free:

1-877-344-7529

International Toll:

1-412-317-0088

Canada Toll Free:

855-669-9658

Replay Access Code:

10070773

 

End Date: Sep 11, 2015

To access the replay using an international dial-in number, please select the link below.
https://services.choruscall.com/ccforms/replay.html

Available 1 hour after the end of the conference.
Participants will be required to state their name and company upon entering the call.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company recently launched its initial product of the planned exVive3DTM portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products are in development, with anticipated release for an exVive3DTM Human Kidney Tissue in the latter half of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com. Sign up for email updates and connect with us on Twitter (@Organovo).

 

SOURCE Organovo Holdings, Inc.



RELATED LINKS

http://www.organovo.com